MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 105-113

  Lv, Lei ^a   Li, Yang ^b   Deng, Hui ^a   Zhang, Cheng ^c   Pu, Youguang ^a   Qian, Liting ^a   Xiao, Jun ^d   Zhao, Weidong ^a   Liu, Qi ^e   Zhang, Daming ^c   Wang, Yingwei ^c   Zhang, Hongyu ^f   He, Yinghua ^f   Zhu, Jingde ^a,f  

^a ANHUI PROVINCIAL CANCER HOSPITAL   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^d ANHUI PROVINCIAL HOSPITAL   (China)

^e HARBIN INSTITUTE OF TECHNOLOGY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bladder cancer; Chemoresistance; DNA damage response; HOXC9; MiR 193a 3p; Oxidative stress

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; HOMEOBOX C9 PROTEIN; HOMEODOMAIN PROTEIN; MICRORNA; MIR 193A 3P; PACLITAXEL; PIRARUBICIN; UNCLASSIFIED DRUG; HOXC9 PROTEIN, HUMAN; MIRN193 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; GENE; GENE TARGETING; HOXC9 GENE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OXIDATIVE STRESS; TUMOR XENOGRAFT; ANIMAL; DRUG RESISTANCE; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

MUS;

ANIMALS; CELL LINE, TUMOR; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; HOMEODOMAIN PROTEINS; HUMANS; MICE; MICE, NUDE; MICRORNAS; TRANSFECTION; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920437719     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.002     Document Type: Article

References (43)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin 2014, 64:9-29.
2. Zhang L., Wu S., Guo L.R., Zhao X.J. Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China. Asian J. Androl 2009, 11:9-13.
3. Cimino G.D., Pan C.-X., Henderson P.T. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis 2013, 5:369-391.
4. Gordon R.R., Nelson P.S. Cellular senescence and cancer chemotherapy resistance. Drug Resist. Updat 2012, 15:123-131.
5. Grossman H.B., Natale R.B., Tangen C.M., Speights V., Vogelzang N.J., Trump D.L., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. NEJM 2003, 349:859-866.
6. Wolff E.M., Liang G., Jones P.A. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat. Clin. Pract. Urol 2005, 2:502-510.
7. Chen H., Yu Y., Rong S., Wang H. Evaluation of diagnostic accuracy of DNA methylation biomarkers for bladder cancer: a systematic review and meta-analysis. Biomarkers 2014, 19:189-197.
8. Kandimalla R., van Tilborg A.A., Zwarthoff E.C. DNA methylation-based biomarkers in bladder cancer. Nat. Rev. Urol 2013, 10:327-335.
9. Anglim P.P., Galler J.S., Koss M.N., Hagen J.A., Turla S., Campan M., et al. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol. Cancer 2008, 7:62.
10. Visone R., Croce C.M. MiRNAs and cancer. Am. J. Pathol 2009, 174:1131-1138.
11. Yoshino H., Seki N., Itesako T., Chiyomaru T., Nakagawa M., Enokida H. Aberrant expression of microRNAs in bladder cancer. Nat. Rev. Urol 2013, 10:396-404.
12. Shi Z., Wei Q., Zhang M., She J. MicroRNAs in bladder cancer: expression profiles, biological functions, regulation, and clinical implications. Crit. Rev. Eukaryot. Gene Expr 2014, 24.
13. Guancial E.A., Bellmunt J., Yeh S., Rosenberg J.E., Berman D.M. The evolving understanding of microRNA in bladder cancer. Urol. Oncol 2014, 41.e31-41.e40.
14. Nordentoft I., Birkenkamp-Demtroder K., Agerbæk M., Theodorescu D., Ostenfeld M.S., Hartmann A., et al. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med. Genomics 2012, 5:40.
15. Dyrskjøt L., Ostenfeld M.S., Bramsen J.B., Silahtaroglu A.N., Lamy P., Ramanathan R., et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009, 69:4851-4860.
16. Heller G., Weinzierl M., Noll C., Babinsky V., Ziegler B., Altenberger C., et al. Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin. Cancer Res 2012, 18:1619-1629.
17. Avci C.B., Harman E., Dodurga Y., Susluer S.Y., Gunduz C. Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac. J. Cancer Prev 2013, 14:765-768.
18. Tahiri A., Leivonen S.K., Luders T., Steinfeld I., Ragle Aure M., Geisler J., et al. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 2014, 35:76-85.
19. Chen D., Cabay R.J., Jin Y., Wang A., Lu Y., Shah-Khan M., et al. MicroRNA deregulations in head and neck squamous cell carcinomas. J. Oral Maxillofac. Res 2013, 4:e2.
20. Yong F.L., Law C.W., Wang C.W. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer 2013, 13:280.
21. Ma K., He Y., Zhang H., Fei Q., Niu D., Wang D., et al. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J. Biol. Chem 2012, 287:5639-5649.
22. Lv L., Deng H., Li Y., Zhang C., Liu X., Liu Q. Cell Death Dis 2014, 5:e1402.
23. Deng H., Lv L., Li Y., Zhang C., Meng F., Pu Y., et al. miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the Oxidative Stress pathway. Mol Cancer 2014, 13:234.
24. Li Y., Gao L., Luo X., Wang L., Gao X., Wang W., et al. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t (8; 21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood 2013, 121:499-509.
25. Iliopoulos D., Rotem A., Struhl K. Inhibition of miR-193a expression by Max and RXRα activates K-Ras and PLAU to mediate distinct aspects of cellular transformation. Cancer Res 2011, 71:5144-5153.
26. Nakano H., Yamada Y., Miyazawa T., Yoshida T. Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int. J. Oncol 2013, 42:1875-1882.
27. Noh H., Hong S., Dong Z., Pan Z.K., Jing Q., Huang S. Impaired microRNA processing facilitates breast cancer cell invasion by upregulating urokinase-type plasminogen activator expression. Genes Cancer 2011, 2:140-150.
28. Salvi A., Conde I., Abeni E., Arici B., Grossi I., Specchia C., et al. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol. Cancer 2013, 12:162.
29. Kwon J.E., Kim B.Y., Kwak S.Y., Bae I.H., Han Y.H. Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1. Apoptosis 2013, 18:896-909.
30. Uhlmann S., Mannsperger H., Zhang J.D., Horvat E.Á., Schmidt C., Küblbeck M., et al. Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol. Syst. Biol 2012, 8.
31. Santarpia L., Calin G.A., Adam L., Ye L., Fusco A., Giunti S., et al. A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr. Relat. Cancer 2013, 20:809-823.
32. Kikuyama M., Takeshima H., Kinoshita T., Okochi-Takada E., Wakabayashi M., Akashi-Tanaka S., et al. Development of a novel approach, the epigenome-based outlier approach, to identify tumor-suppressor genes silenced by aberrant DNA methylation. Cancer Lett 2012, 322:204-212.
33. Lin Q., Geng J., Ma K., Yu J., Sun J., Shen Z., et al. RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. J. Cancer Res. Clin. Oncol 2009, 135:1675-1684.
34. Wang X., Choi J.-H., Ding J., Yang L., Ngoka L.C., Lee E.J., et al. HOXC9 directly regulates distinct sets of genes to coordinate diverse cellular processes during neuronal differentiation. BMC Genomics 2013, 14:830.
35. Luo L., Yang X., Takihara Y., Knoetgen H., Kessel M. The cell-cycle regulator geminin inhibits Hox function through direct and polycomb-mediated interactions. Nature 2004, 427:749-753.
36. Zhu W., DePamphilis M.L. Selective killing of cancer cells by suppression of geminin activity. Cancer Res 2009, 69:4870-4877.
37. Hall J.R., Lee H.O., Bunker B.D., Dorn E.S., Rogers G.C., Duronio R.J., et al. Cdt1 and Cdc6 are destabilized by rereplication-induced DNA damage. J. Biol. Chem 2008, 283:25356-25363.
38. Saxena S., Dutta A. Geminin and p53. Cell Cycle 2003, 2:283-286.
39. Ravasi T., Suzuki H., Cannistraci C.V., Katayama S., Bajic V.B., Tan K., et al. An atlas of combinatorial transcriptional regulation in mouse and man. Cell 2010, 140:744-752.
40. Li Z., Hou J., Sun L., Wen T., Wang L., Zhao X., et al. NMI mediates transcription-independent ARF regulation in response to cellular stresses. Mol. Biol. Cell 2012, 23:4635-4646.
41. Goettsch C., Goettsch W., Brux M., Haschke C., Brunssen C., Muller G., et al. Arterial flow reduces oxidative stress via an antioxidant response element and Oct-1 binding site within the NADPH oxidase 4 promoter in endothelial cells. Basic Res. Cardiol 2011, 106:551-561.
42. Lin X., Yang H., Zhang H., Zhou L., Guo Z. A novel transcription mechanism activated by ethanol induction of Slc7a11 gene expression via inhibition of the DNA-binding activity of transcriptional repressor octamer-binding transcription factor 1 (OCT-1). J. Biol. Chem 2013, 288:14815-14823.
43. Thum T., Borlak J. LOX-1 receptor blockade abrogates oxLDL-induced oxidative DNA damage and prevents activation of the transcriptional repressor Oct-1 in human coronary arterial endothelium. J. Biol. Chem 2008, 283:19456-19464.